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Health technology assessment
and public health: a commentary
Walter W. Holland
London School of Economics & Political Science
This article reviews the developments in HTA in four countries, France, The Netherlands,
Sweden, and United Kingdom, in relation to public health. It emphasizes that the majority
of assessments made are concerned with individual clinical care rather than with the
optimization of health. Possible reasons for the neglect of public health issues are that
these are inherently more complex than the assessment of individual procedures or
drugs. They are usually multisectoral, politically charged, and often considered mundane
and “common sense” and, thus, not requiring evaluation (although when evaluations are
done they are often counterintuitive). Unless more emphasis is given to the development
and evaluation of public health measures, it is unlikely that there will be any major
advances in health status. Possible areas for future assessment should include such
issues as smoking, drug and other substance misuse, nutrition, and health inequalities.
However, it is unlikely that these major areas of concern will be included in the future
unless the methods of choice for priorities of development and assessment are changed
to include measures that improve health status rather than only clinical services.
Keywords: Health technology assessment, Public health
Formal evaluation of procedures and equipment, including
pharmaceutical agents, has become the norm in most health
services. This development of the use of evidence to influence
practice is welcome. A particularly interesting development
has been the creation of formally designated centres for the as-
sessment of health technology in several countries. “Criteria
for the assessment of health technology have been developed
and the field has become rapidly professionalized, with an
emerging consensus on procedures and key findings” (1).
This special issue contains articles that describe the
experience in four countries. It is interesting to observe the
similarity, as well as the differences, in these. From the public
health perspective, the interpretation of meaning is important.
Health has been defined in the preamble to the consti-
tution of the World Health Organization, “Health is a state
of complete physical, mental, and social well being, and not
merely the absence of disease or infirmity” (3).
Health problems vary in different parts of the world but
can be grouped under communicable disease, noncommuni-
cable disease, trauma, and mental disorders. It is generally
accepted that the major determinants of health are nutrition,
environmental and occupational hazards, lifestyle, income,
and biological factors such as genetics. Clinical or medical
care services undoubtedly contribute to levels of health but
are of a much lesser order of magnitude than the above
listed determinants. It is noteworthy that the four studies
largely cover the assessment of clinical procedures, drugs,
techniques, and equipment.
The French government has a National Agency for
Accreditation and Evaluation in Health (ANAES). It has had a
role in contributing to health policy by its recommendations
on screening, for example, for breast cancer (positive) and
hemochromatosis (negative). ANAES is stated as addressing
public health programs on cancer, cardiovascular disease, and
diabetes, but no examples are given of evaluations on actually
preventing these conditions.
The Swedish study is more careful in its use of terminol-
ogy for HTA as it talks of medical technology and health.
It is of particular interest that Sweden’s early initiatives
were on polio vaccination and water fluoridation. This study
also emphasizes the stimulus provided by the US Office
of Technology Assessment, which were largely concerned
with “big ticket” (expensive) technologies. This contribution
emphasizes that, after this original concern with services to
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improve health, the next period was largely devoted to the
assessment of medical technologies and clinical procedures.
Only more recently have the projects again become con-
cerned with the wider problems of health and prevention,
e.g., tobacco and oral health or the prevention of obesity.
This has been linked to the treatment of specific conditions,
for example, anxiety states, depression, and psychosis, and
not only the assessment of individual drugs or procedures.
The authors emphasize the need for more critical assessment
of the complex interventions of health promotion activities,
organizational changes or caring for individual groups of the
population such as the elderly. They accept that the methods
and criteria for these will need to be different (and probably
more complex) than those used in clinical research.
In The Netherlands, economic evaluations were intro-
duced in response to high-cost health technologies such as
heart and liver transplantations. Later assessments were con-
cerned with routinely used services, for example, psycho-
therapy and cancer drugs.
In the United Kingdom, HTA is also primarily concerned
with the evaluation of clinical procedures including screening
(which can be classified as secondary prevention). Of the
117 National Health Service’s Research and Development
program (the NHS R&D program) reports published between
1997 and 2001, 19 were concerned with screening services,
and 28 were methodological—for example, Bayesian meth-
ods, assessment of costs in randomized control trials, and
publication biases. Several were concerned with services
for specific groups—for example, outpatient services for
chronic pain control. Only one was concerned with pri-
mary prevention—“health promoting schools and health
promotion in schools: two systematic reviews.” The authors
describe with great clarity the various mechanisms that have
been put in place and the differences between assessment and
appraisal.
PUBLIC HEALTH AND HTA
These studies illustrate the problem that public health faces.
There is little dispute about the relative contributions that
public health and clinical measures can make to the improve-
ments of health status of populations. But we are confounded
by the terms and language we use. Terminology often leads to
misunderstanding. Thus, the difference between private and
public health, for example, requires clarification. The term
clinical services describes more aptly those health services
that focus on the cure and care of individual patients, whether
these are publicly or privately financed. An effective public
health service identifies and responds to health problems to
protect the health of populations. It is unfortunate that the
term health technology assessment (HTA) has taken on such
a universal usage—as shown in the studies, and discussed
here, the majority of subjects tackled are concerned with
individual clinical care rather than with the optimization of
health.
If one considers the history of the development of formal
assessment of technical procedures to improve and main-
tain health, the best examples are in the field of immuniza-
tion, where large-scale trials of vaccines were carried out, for
example, diphtheria, poliomyelitis (both the killed and live
vaccines), and measles. These rarely included the economic
assessments now deemed mandatory, although rough esti-
mates of resource consequences were made. The assessments
of benefits were in terms of mortality or cases.
A good example of the assessment of changes in practice
to prevent maternal mortality in the 1930s were the studies
by Colebrook and colleagues of the ways in which delivery
in hospital needed to be changed to reduce the risk of strepto-
coccal infection. Again these studies did not include formal
economic assessments.
In most of the examples quoted from the four coun-
tries, the consideration of topics appears limited to drugs,
equipment, and a few services, for example, transplantation.
Although HTA requires sophisticated economic analyses of
the procedures examined, there would seem to be a gap in the
use of economic assessments of what actually is important
in improving health. From the public health viewpoint, this
is far too narrow a perspective. Obviously, there is a need to
evaluate different types of hip prostheses or transplantation
(to give just two examples), but these are not necessarily the
major “drivers” of health concerns.
It is perfectly understandable why some types of drugs
have been included in HTA evaluations—their cost may be
very high; thus, it is important to balance these with the ben-
efits. However, the treatment of the appropriate individuals
with such drugs, although of benefit to the individual, will
have little effect on the health status of the population.
The rigorous examination of screening procedures in all
four countries has an effect on population health status. It is,
however, disappointing that, except in Sweden, there appears
to be little effort to tackle the assessment of measures which
might have a large effect on health, rather than on only clinical
services.
Examples that would lend themselves to tackling issues
of health might be technological measures to reduce the in-
cidence of accidents in childhood, for example, measures to
reduce road accidents or fires in the home. A major social and
health problem, particularly in inner city areas, is pregnancy
in women under 16 years, or even single parenthood. Clearly
these are very much more difficult areas to tackle than which
screening tests to use or how to manage dyspepsia—but tack-
ling them, and providing guidance, might have an important
effect on health status.
POSSIBLE REASON FOR THE DEARTH
OF PUBLIC HEALTH ISSUES IN HTA
There are several possible reasons why HTA has not engaged
in public health issues. First, public health programs are in-
herently far more complex to evaluate than, for example, a
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new drug or diagnostic procedure. In the former case, one
aims to identify beneficial effects in terms of function or out-
come as measured by mortality and side-effects. In the latter
case, the end point is usually an improvement in diagnosis. A
public health program may lead to lower mortality (or mor-
bidity), but this is usually on a far longer time scale than, for
example, the effect of treatment on a patient with a disease
with a new drug. The change in smoking habits as a result
of antismoking measures took many years to be evident in
mortality (or morbidity). Many public health measures may
lead to changes in attitude—but behavior change and im-
proved outcome, except in rare instances, take a long time to
occur.
Second, the introduction of public health measures
are often complex and require the cooperation of multi-
ple agencies or organizations, as well as often involving
payment by individuals from their own resources and chang-
ing their behaviors. A good example was the introduction
of the Clean Air Act in 1956, which entailed a change in
the way homes were heated. Of course, this measure has
had a dramatic effect on both health and the environment, as
seen after approximately 15 years. Thus, not only is the time
scale different for the introduction of a new drug/machine,
but the degree of complexity is of a different order of
magnitude.
Third, public health interventions are frequently politi-
cally charged and resisted by powerful groups. An example in
the nineteenth century was the resistance to the introduction
of sanitary regulations, which was opposed by landlords
and shopkeepers. Currently, tobacco control and tobacco
advertising is a good example of how powerful economic in-
dustries, allied to their political friends, can stymie suggested
public health measures—and their evaluation.
Fourth, it must not be forgotten that many public health
measures are considered to be common sense, or obvious, and
proper assessment is resisted—for example, the usefulness
of routine health examinations in the middle aged (shown
to have no effect on mortality or morbidity and yet still
propagated by many).
Fifth, another obstacle to HTA neglect of public health
is the lack of charisma of public health measures—cleaning
up the water supply or adding fluoride to water is far less
newsworthy than evaluating a new molecular drug or shiny
piece of machinery that is promoted by powerful industrial
groups and their client-media. Because priorities for HTA
are not set by individuals concerned with wider public health
issues but by clinicians, nurses, managers, consumers, etc.,
it is not surprising that public health issues take a back
seat.
As I mention below, unless there is a major improvement
in both the funding for public health research, the standing
and influence of public health in the setting of health (not clin-
ical) priorities, and in the number of well-trained researchers
and implementers of public health research, it is unlikely that
much change in the status quo will occur.
SUGGESTED FRAMEWORK FOR
INCLUSION OF PUBLIC HEALTH
ISSUES IN HTA
If public health issues are to be included in HTA it is crucial
that there be both agreement on their objectives as well as
their prioritization. The actual design of a public health HTA
would follow accepted research methodology.
Possible outcomes for public health would include:
(a) improved health status,
(b) risk factor reduction,
(c) improved services and protection,
(d) appropriate methods for continuing surveillance.
Examples of areas where public health measures need
to be developed and assessed are smoking, alcohol-related
harm, drug and other substance misuse, nutrition, accidental
injuries, birth control, physical and sensory disability, and
health inequalities.
In each of these areas, all of major importance to health
and health services, the possible, promising interventions
would need to be identified. The population “at risk” and
suitable measures of outcome, as outlined above, need to be
identified, developed, and applied. The time scale for an eval-
uation would depend on the problem and the size of the trial—
for example, an evaluation of measures to reduce childhood
accidents could, probably, be achieved in a 2-year period if the
size of the exposed population was large enough (5–10 large
primary schools). The evaluation of methods to promote less
conceptions in girls below age 15 is likely to be somewhat
lengthier—3–5 years at best. The problems are likely to arise
in both identifying and prioritizing suitable technologies for
assessment as well as gaining the necessary participation of
appropriate test and control populations—all of whom would
consider themselves healthy in contrast to patients with a
disease or problem.
OTHER ISSUES INCLUDED AND OMITTED
IN HTA
Although the topics chosen by each of the countries include
some examples of assessment of organizational structures,
none address some of the major issues that need to be ad-
dressed. No examples are given of the assessment of different
types of personnel to deal with medical issues—for example,
do we need to see a doctor, and if not, would a nurse do?
Although call services have been introduced in the
United Kingdom, they have not been evaluated with the
same rigor as individual drugs—and yet they have far greater
consequences. This narrowness of approach to evaluate what
is easy and simple to do is undoubtedly necessary—and has
changed the climate for the acceptance of proper evaluation—
but is very limited in its effect on the methods and costs
of health service delivery. A far more open and wider
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perspective is required if we are to improve the health of
the public rather than only improve the delivery of individual
clinical services.
Stevens and Milne comment that, in the United
Kingdom, the major stimulus to HTA was the House of
Lords Report on Priorities in Medical Research (2), but they
fail to say that the major aims of the committee have been
neglected. Certainly, the creation of the NHS R&D Direc-
torate has had a powerful effect in increasing activity in health
services research. But, as I have pointed out above, this is
not equivalent to public health. The Committee emphasized
the need to “encourage the long-term development of public
health and operational research. The Committee have no
doubt that these are areas of research which would repay—
literally repay—investment. The Committee recommend that
spending in these areas should, therefore, be markedly
increased” (para 4.13). “The Committee believe that these
recommendations underpin, rather than duplicate, the recom-
mendations made in the Acheson Report on “Public Health”
in England . . . Monitoring of health is not enough: systematic
public health research must be undertaken . . . .” (para 4.14).
It is unfortunate that, since the publication of the House
of Lords Report, the issues considered of primary impor-
tance in improving public health research capability, which
would enable public health issues to be tackled under the
HTA umbrella in the UK, have been neglected at the expense
of concentrating on what some would term relatively trivial
issues concerned with individual clinical services rather than
health.
CONCLUSION
The concentration by HTA on single drugs or procedures such
as neonatal screening is understandable. These issues can be
defined with reasonable clarity, and suitable studies/data are
available or can be commissioned easily. They are of immedi-
ate relevance and interest to both industry and the providers of
clinical services. From the public health point of view, most
of the programs described are disappointing and irrelevant.
Concentrating on drugs and clinical procedures does not re-
ally have a great influence on population health. The use of
the term health technology assessment is misleading, because
most assessments are limited to a single technology or instru-
ment, omitting other possible solutions for tackling a partic-
ular problem. For example, it will investigate a single proce-
dure such as heart surgery but fails to put it into context with
other options to reduce either the incidence of heart disease or
other means of reducing mortality and disability from heart
disease. Of course, this is much more difficult, but essential
if the objective is a national, effective, efficient health policy.
In England, Stevens and Milne describe some of the other
agencies or mechanisms that have been introduced—for ex-
ample, Health Service Delivery Organisation, NICE, etc. But
although they and the other authors state that a formal prior-
itization process exists and is discussed, no details are given
of the framework within which priorities are allocated. For
example, whether the procedures to be assessed are primarily
concerned with a reduction of disability and an improvement
of quality of life, or a reduction of mortality. Similarly, in the
examples given, it is difficult to understand the relation be-
tween those chosen and the burden of disease—particularly
in the United Kingdom (for example, 2 of 117 HTA
reviews between 1997 and 2001 were on “fragile x” syndrome
screening—a very rare condition, while there was none on
screening for coronary heart disease, a common condition).
Thus, it may be seen that, although the HTA programs may
be important, both their design and content is of little public
health significance. This is a great pity—only the Swedes ap-
pear to have made attempts to include health in addition to
clinical issues.
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